University of Barcelona (UB) and Hospital Clinic de Barcelona collaborate with Boehringer Ingelheim Inc. to improve the effectiveness of nintedanib, an antiangiogenic and antifibrotic drug, for the treatment of lung cancer. The findings of the study are published in the journal iCancer Research/i.
This public-private collaboration enabled researchers to identify molecular mechanisms underlying the lack of efficiency of this drug in squamous cell carcinoma, a sub-type of non-small cell lung ...
University of Barcelona (UB) and Hospital Clinic de Barcelona collaborate with Boehringer Ingelheim Inc. to improve the effectiveness of nintedanib, an antiangiogenic and antifibrotic drug, for the treatment of lung cancer. The findings of the study are published in the journal iCancer Research/i.
This public-private collaboration enabled researchers to identify molecular mechanisms underlying the lack of efficiency of this drug in squamous cell carcinoma, a sub-type of non-small cell lung ...